Curasight has announced preliminary data from the first patient dosed in its phase I trial evaluating uTREAT in high-grade gliomas. The results show clear and sustained uptake of the radiopharmaceutical in the tumor, supporting the potential of the company’s uPAR-targeted theranostic platform. BioStock contacted CEO Ulrich Krasilnikoff to get his thoughts on this milestone.
Read the full interview at biostock.se:
Curasight reports encouraging preliminary data from uTREAT Phase I study
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/